Selected research
Market Structure
Global ADCC Enhanced Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global ADCC Enhanced Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for ADCC Enhanced Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for ADCC Enhanced Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for ADCC Enhanced Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for ADCC Enhanced Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of ADCC Enhanced Antibody include C.H. Boehringer Sohn, Daiichi Sankyo, Jazz Pharmaceuticals, MacroGenics, Merus NV, Novartis AG, Puma Biotechnology, Roche Holding AG and Takeda Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global ADCC Enhanced Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of ADCC Enhanced Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents ADCC Enhanced Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the ADCC Enhanced Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.
ADCC Enhanced Antibody Segment by Company
C.H. Boehringer Sohn
Daiichi Sankyo
Jazz Pharmaceuticals
MacroGenics
Merus NV
Novartis AG
Puma Biotechnology
Roche Holding AG
Takeda Pharmaceutical
Dizal (Jiangsu) Pharmaceutical
Hengrui Medicine
Pfizer
RemeGen Biopharma
Sansheng Guojian
ADCC Enhanced Antibody Segment by Type
Fc Fusion Protein
Monospecific Antibody
Polyspecific Antibody
Antibody Fusion Protein
ADCC Enhanced Antibody Segment by Application
Hospital
Clinic
Others
ADCC Enhanced Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ADCC Enhanced Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of ADCC Enhanced Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ADCC Enhanced Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the ADCC Enhanced Antibody market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ADCC Enhanced Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of ADCC Enhanced Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of ADCC Enhanced Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Fc Fusion Protein
- Monospecific Antibody
- Polyspecific Antibody
- Antibody Fusion Protein
Applications
- Hospital
- Clinic
- Others
Companies covered
- C.H. Boehringer Sohn
- Daiichi Sankyo
- Jazz Pharmaceuticals
- MacroGenics
- Merus NV
- Novartis AG
- Puma Biotechnology
- Roche Holding AG
- Takeda Pharmaceutical
- Dizal (Jiangsu) Pharmaceutical
- Hengrui Medicine
- Pfizer
- RemeGen Biopharma
- Sansheng Guojian
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global ADCC Enhanced Antibody Market Size, 2021 VS 2025 VS 2032
- 1.3 Global ADCC Enhanced Antibody Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global ADCC Enhanced Antibody Sales Estimates and Forecasts (2021-2032)
- 1.5 Global ADCC Enhanced Antibody Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global ADCC Enhanced Antibody Market Dynamics
- 2.1 ADCC Enhanced Antibody Industry Trends
- 2.2 ADCC Enhanced Antibody Industry Drivers
- 2.3 ADCC Enhanced Antibody Industry Opportunities and Challenges
- 2.4 ADCC Enhanced Antibody Industry Restraints
3 ADCC Enhanced Antibody Market by Manufacturers
- 3.1 Global ADCC Enhanced Antibody Revenue by Manufacturers (2021-2026)
- 3.2 Global ADCC Enhanced Antibody Sales by Manufacturers (2021-2026)
- 3.3 Global ADCC Enhanced Antibody Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global ADCC Enhanced Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global ADCC Enhanced Antibody Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global ADCC Enhanced Antibody Manufacturers, Product Type & Application
- 3.7 Global ADCC Enhanced Antibody Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global ADCC Enhanced Antibody Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 ADCC Enhanced Antibody Players Market Share by Revenue in 2025
- 3.8.3 2025 ADCC Enhanced Antibody Tier 1, Tier 2, and Tier 3
4 ADCC Enhanced Antibody Market by Type
- 4.1 ADCC Enhanced Antibody Type Introduction
- 4.1.1 Fc Fusion Protein
- 4.1.2 Monospecific Antibody
- 4.1.3 Polyspecific Antibody
- 4.1.4 Antibody Fusion Protein
- 4.2 Global ADCC Enhanced Antibody Sales by Type
- 4.2.1 Global ADCC Enhanced Antibody Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global ADCC Enhanced Antibody Sales by Type (2021-2032)
- 4.2.3 Global ADCC Enhanced Antibody Sales Market Share by Type (2021-2032)
- 4.3 Global ADCC Enhanced Antibody Revenue by Type
- 4.3.1 Global ADCC Enhanced Antibody Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global ADCC Enhanced Antibody Revenue by Type (2021-2032)
- 4.3.3 Global ADCC Enhanced Antibody Revenue Market Share by Type (2021-2032)
5 ADCC Enhanced Antibody Market by Application
- 5.1 ADCC Enhanced Antibody Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global ADCC Enhanced Antibody Sales by Application
- 5.2.1 Global ADCC Enhanced Antibody Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global ADCC Enhanced Antibody Sales by Application (2021-2032)
- 5.2.3 Global ADCC Enhanced Antibody Sales Market Share by Application (2021-2032)
- 5.3 Global ADCC Enhanced Antibody Revenue by Application
- 5.3.1 Global ADCC Enhanced Antibody Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global ADCC Enhanced Antibody Revenue by Application (2021-2032)
- 5.3.3 Global ADCC Enhanced Antibody Revenue Market Share by Application (2021-2032)
6 Global ADCC Enhanced Antibody Sales by Region
- 6.1 Global ADCC Enhanced Antibody Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global ADCC Enhanced Antibody Sales by Region (2021-2032)
- 6.2.1 Global ADCC Enhanced Antibody Sales by Region (2021-2026)
- 6.2.2 Global ADCC Enhanced Antibody Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America ADCC Enhanced Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America ADCC Enhanced Antibody Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe ADCC Enhanced Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe ADCC Enhanced Antibody Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific ADCC Enhanced Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific ADCC Enhanced Antibody Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa ADCC Enhanced Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa ADCC Enhanced Antibody Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global ADCC Enhanced Antibody Revenue by Region
- 7.1 Global ADCC Enhanced Antibody Revenue by Region
- 7.1.1 Global ADCC Enhanced Antibody Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global ADCC Enhanced Antibody Revenue by Region (2021-2026)
- 7.1.3 Global ADCC Enhanced Antibody Revenue by Region (2027-2032)
- 7.1.4 Global ADCC Enhanced Antibody Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America ADCC Enhanced Antibody Revenue (2021-2032)
- 7.2.2 North America ADCC Enhanced Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe ADCC Enhanced Antibody Revenue (2021-2032)
- 7.3.2 Europe ADCC Enhanced Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific ADCC Enhanced Antibody Revenue (2021-2032)
- 7.4.2 Asia-Pacific ADCC Enhanced Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa ADCC Enhanced Antibody Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa ADCC Enhanced Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 C.H. Boehringer Sohn
- 8.1.1 C.H. Boehringer Sohn Company Information
- 8.1.2 C.H. Boehringer Sohn Business Overview
- 8.1.3 C.H. Boehringer Sohn ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 C.H. Boehringer Sohn ADCC Enhanced Antibody Product Portfolio
- 8.1.5 C.H. Boehringer Sohn Recent Developments
- 8.2 Daiichi Sankyo
- 8.2.1 Daiichi Sankyo Company Information
- 8.2.2 Daiichi Sankyo Business Overview
- 8.2.3 Daiichi Sankyo ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Daiichi Sankyo ADCC Enhanced Antibody Product Portfolio
- 8.2.5 Daiichi Sankyo Recent Developments
- 8.3 Jazz Pharmaceuticals
- 8.3.1 Jazz Pharmaceuticals Company Information
- 8.3.2 Jazz Pharmaceuticals Business Overview
- 8.3.3 Jazz Pharmaceuticals ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Jazz Pharmaceuticals ADCC Enhanced Antibody Product Portfolio
- 8.3.5 Jazz Pharmaceuticals Recent Developments
- 8.4 MacroGenics
- 8.4.1 MacroGenics Company Information
- 8.4.2 MacroGenics Business Overview
- 8.4.3 MacroGenics ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 MacroGenics ADCC Enhanced Antibody Product Portfolio
- 8.4.5 MacroGenics Recent Developments
- 8.5 Merus NV
- 8.5.1 Merus NV Company Information
- 8.5.2 Merus NV Business Overview
- 8.5.3 Merus NV ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Merus NV ADCC Enhanced Antibody Product Portfolio
- 8.5.5 Merus NV Recent Developments
- 8.6 Novartis AG
- 8.6.1 Novartis AG Company Information
- 8.6.2 Novartis AG Business Overview
- 8.6.3 Novartis AG ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Novartis AG ADCC Enhanced Antibody Product Portfolio
- 8.6.5 Novartis AG Recent Developments
- 8.7 Puma Biotechnology
- 8.7.1 Puma Biotechnology Company Information
- 8.7.2 Puma Biotechnology Business Overview
- 8.7.3 Puma Biotechnology ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Puma Biotechnology ADCC Enhanced Antibody Product Portfolio
- 8.7.5 Puma Biotechnology Recent Developments
- 8.8 Roche Holding AG
- 8.8.1 Roche Holding AG Company Information
- 8.8.2 Roche Holding AG Business Overview
- 8.8.3 Roche Holding AG ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Roche Holding AG ADCC Enhanced Antibody Product Portfolio
- 8.8.5 Roche Holding AG Recent Developments
- 8.9 Takeda Pharmaceutical
- 8.9.1 Takeda Pharmaceutical Company Information
- 8.9.2 Takeda Pharmaceutical Business Overview
- 8.9.3 Takeda Pharmaceutical ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Takeda Pharmaceutical ADCC Enhanced Antibody Product Portfolio
- 8.9.5 Takeda Pharmaceutical Recent Developments
- 8.10 Dizal (Jiangsu) Pharmaceutical
- 8.10.1 Dizal (Jiangsu) Pharmaceutical Company Information
- 8.10.2 Dizal (Jiangsu) Pharmaceutical Business Overview
- 8.10.3 Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Product Portfolio
- 8.10.5 Dizal (Jiangsu) Pharmaceutical Recent Developments
- 8.11 Hengrui Medicine
- 8.11.1 Hengrui Medicine Company Information
- 8.11.2 Hengrui Medicine Business Overview
- 8.11.3 Hengrui Medicine ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Hengrui Medicine ADCC Enhanced Antibody Product Portfolio
- 8.11.5 Hengrui Medicine Recent Developments
- 8.12 Pfizer
- 8.12.1 Pfizer Company Information
- 8.12.2 Pfizer Business Overview
- 8.12.3 Pfizer ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Pfizer ADCC Enhanced Antibody Product Portfolio
- 8.12.5 Pfizer Recent Developments
- 8.13 RemeGen Biopharma
- 8.13.1 RemeGen Biopharma Company Information
- 8.13.2 RemeGen Biopharma Business Overview
- 8.13.3 RemeGen Biopharma ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 RemeGen Biopharma ADCC Enhanced Antibody Product Portfolio
- 8.13.5 RemeGen Biopharma Recent Developments
- 8.14 Sansheng Guojian
- 8.14.1 Sansheng Guojian Company Information
- 8.14.2 Sansheng Guojian Business Overview
- 8.14.3 Sansheng Guojian ADCC Enhanced Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Sansheng Guojian ADCC Enhanced Antibody Product Portfolio
- 8.14.5 Sansheng Guojian Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 ADCC Enhanced Antibody Value Chain Analysis
- 9.1.1 ADCC Enhanced Antibody Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 ADCC Enhanced Antibody Production Mode & Process
- 9.2 ADCC Enhanced Antibody Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 ADCC Enhanced Antibody Distributors
- 9.2.3 ADCC Enhanced Antibody Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst